346: Zealand's obesity strategy and Immunovant's curious development plan
The Readout Loud
00:00
Immunivant's Strategic Shift After Phase Three Success
This chapter explores the recent phase three trial results for Immunivant's autoimmune drug beta-climab, targeting myasthenia gravis. Despite promising outcomes, the company opts to pursue a safer successor drug, while also examining market valuations compared to a rival biotech firm.
Transcript
Play full episode
